Neuroscience Market Size Estimates and Forecasts [2022-2027] | In-Depth Analysis of Market Status, Growing CAGR of 3.5%, Industry Share, Emerging Trends, Production Capacity, Revenue, Price, Gross Margin and Cost Structures
March 30, 2022 05:34 ET
|
Industry Research
Pune, March 30, 2022 (GLOBE NEWSWIRE) -- “Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Neuroscience Market” is a comprehensive research that provides...
XCPCNL Business Services Announces LOI to Acquire Centiment Capital Holdings
March 15, 2022 08:00 ET
|
XCPCNL Business Services Corporation
Charlotte, North Carolina, March 15, 2022 (GLOBE NEWSWIRE) -- XCPCNL Business Services Corporation (OTC Pink: XCPL), a venture development business that leverages knowledge, skill, and experience in...
Dr. David Margulies and Dr. Hal C. Lewis Present HEALING and REGENERATING the INJURED BRAIN
January 19, 2022 14:00 ET
|
The Dan Lewis Foundation for Brain Regeneration Research
DENVER, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Talks at Google, a global talk series, recently presented Healing and Regenerating the Injured Brain with Dr. Hal Lewis and Dr. David Margulies. Drs. Lewis...
CenExel Clinical Research Acquires California Neuroscience Research
January 10, 2022 13:10 ET
|
CenExel Clinical Research
Salt Lake City, Utah, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of California Neuroscience Research (“CenExel CNR”), a clinical...
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent
January 04, 2022 01:15 ET
|
Novartis Pharma AG
Basel, January 4, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US Patent No. 9,187,405 covering a dosing...
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001 at Neuroscience 2021
November 08, 2021 08:00 ET
|
Neurona Therapeutics
IND cleared by the FDA to enable initiation of Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant focal epilepsy Supporting preclinical data demonstrate seizure-freedom in up to 68%...
Former U.S. Congressman Fattah Calls for African Brain Research Fund During Global Neuroscience Conference
October 28, 2021 17:57 ET
|
Fattah Neuroscience Global Advisors
Accra, Ghana / Philadelphia, PA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Today, former United States Congressman and CEO of Fattah Neuroscience Global Advisors, Chaka Fattah, delivered a powerful virtual...
Nexstim’s SmartFocus® TMS Technology Used in Award-Winning Project Addressing Disorders of Consciousness after Severe Brain Injury
October 15, 2021 02:00 ET
|
Nexstim Oyj
Press release, Helsinki, 15 October 2021 at 9 AM (EEST) Nexstim’s SmartFocus® TMS Technology Used in Award-Winning Project Addressing Disorders of Consciousness after Severe Brain Injury Nexstim Plc...
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
September 10, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris,...
Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training
July 21, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
London, UK – 21 July 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...